Electromedical Technologies AI Stock Analysis
Want to see EMED full AI Analyst Report?
Electromedical Technologies (EMED) AI Stock Analysis
Electromedical Technologies
(Other OTC:EMED)
The overall score for EMED reflects significant financial challenges, characterized by negative profitability and high leverage. Although there are no significant insights from technical analysis or earnings calls, the low valuation score due to ongoing losses and lack of dividends further impacts the stock's attractiveness. Improvements in cash flow management are noted but are insufficient to mitigate the broader financial instability.
Electromedical Technologies (EMED) vs. SPDR S&P 500 ETF (SPY)
Not enough price history over this period.
- Market Cap
- $373.23K
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -0.2
- Beta (1Y)
- 38.89
- Revenue Growth
- -66.56%
- EPS Growth
- 69.23%
- Country
- US
- Employees
- 6
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Electromedical Technologies Business Overview & Revenue Model
Company Description
Electromedical Technologies, Inc. operates within the U.S. market, specializing in the creation and distribution of bioelectronic medical devices specifically designed for pain management. The company's primary product is WellnessPro Plus, a prescrip...
How the Company Makes Money
Electromedical Technologies generates revenue primarily through the sale of its bioelectronic devices directly to consumers, healthcare providers, and through distribution partnerships. The company's revenue model includes direct sales, leasing optio...
Electromedical Technologies Peers Comparison
Overall Rating
NCEL48Neutral
BJDX44Neutral
EMED34Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | $14.05M | 7.91 | 21.75% | ― | ― | ― | |
| 44Neutral | $2.92M | -0.11 | -113.80% | ― | ― | 95.46% | |
| 34Underperform | $373.23K | -0.22 | 44.04% | ― | -66.56% | 69.23% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| EMED | Electromedical Technologies, Inc. | ― | ― | ― | |
| ERNA | Eterna Therapeutics Inc. | 1.68 | -36.07 | -95.55% | |
| NCEL | Newcelx Ltd. | 2.61 | -0.87 | -25.00% | |
| BJDX | Bluejay Diagnostics, Inc. | 2.61 | -20.27 | -88.59% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2024
